Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 1.93 USD 3.21% Market Closed
Market Cap: 159.1m USD
Have any thoughts about
Sutro Biopharma Inc?
Write Note

Sutro Biopharma Inc
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sutro Biopharma Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Sutro Biopharma Inc
NASDAQ:STRO
Other
$1.6m
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other
-$100m
CAGR 3-Years
45%
CAGR 5-Years
22%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Other
-$5.7B
CAGR 3-Years
-238%
CAGR 5-Years
-114%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Other
-$127m
CAGR 3-Years
-6%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other
-$398.9m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other
-$1.3B
CAGR 3-Years
-38%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
No Stocks Found

Sutro Biopharma Inc
Glance View

Market Cap
159m USD
Industry
Biotechnology

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.

STRO Intrinsic Value
3.06 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Sutro Biopharma Inc's Other?
Other
1.6m USD

Based on the financial report for Sep 30, 2024, Sutro Biopharma Inc's Other amounts to 1.6m USD.

What is Sutro Biopharma Inc's Other growth rate?
Other CAGR 5Y
-19%

Over the last year, the Other growth was -99%.

Back to Top